ReviewNature reviews. Cancer2009
Mucins in cancer: function, prognosis and therapy.
Review in Nature reviews. Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 795 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
795 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,391 citations in OpenAlex.
- Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis.British journal of cancer · 2026Pooled it
- Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL-KrasMolecular carcinogenesis · 2026Article
- ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window.Molecular cancer therapeutics · 2026Article
- Enzyme-mediated remodeling of the extracellular matrix and glycocalyx to enhance immunotherapy in solid tumors.Bioengineering & translational medicine · 2026Review
- Stage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities.Biomolecules · 2026Review
- Multiplexed Detection of Cancer Protein Biomarkers via Surface-Enhanced Raman Scattering Immunoassays on Natural Diatomite Strips.Chemphyschem : a European journal of chemical physics and physical chemistry · 2026Article
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Esophageal adenosquamous carcinoma with mucinous carcinoma-predominant lymph node metastases: a case report.General thoracic and cardiovascular surgery cases · 2026Article
- Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway.Bioactive materials · 2026Article
- Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nature communications · 2026Article
- M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.bioRxiv : the preprint server for biology · 2026Article
- Fluorinated carbohydrate-based vaccines.Chemical science · 2026Review
- An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.Developmental cell · 2026Article
- Glycosite mapping and in situ mass spectrometry imaging of MUC2 glycopeptides via on-slide mucinase digestion.Nature communications · 2026Article
- Rosmarinic Acid Ameliorates PMAnimals : an open access journal from MDPI · 2026Article
- L-serine at the crossroads of microbiota, intestinal health, and disorders.Communications biology · 2026Review
- Rare Adventitial Venous Cyst Mimicking Deep Vein Thrombosis: A Diagnostic Pitfall-A Systematic Review of Diagnostic Challenges, Imaging Features, and Optimal Treatment Strategies.Journal of clinical medicine · 2026Article
- Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Novel Perspectives on the Relationship Between the Gastrointestinal Mucus Barrier and Soybean Agglutinin.Cells · 2026Review
- The protease cathepsin K can debulk the cancer glycocalyx.The Journal of biological chemistry · 2026Article
735 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Epithelia are protected from adverse conditions by a mucous barrier. The secreted and transmembrane mucins that constitute the mucous barrier are largely unrecognized as effectors of carcinogenesis. However, both types of mucins are intimately involved in inflammation and cancer. Moreover, diverse human malignancies overexpress transmembrane mucins to exploit their role in signalling cell growth and survival. Mucins have thus been identified as markers of adverse prognosis and as attractive therapeutic targets. Notably, the findings that certain transmembrane mucins induce transformation and promote tumour progression have provided the experimental basis for demonstrating that inhibitors of their function are effective as anti-tumour agents in preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.